Rehospitalization Is Driving Costs in Pulmonary Arterial Hypertension

November/December 2013, Vol 6, No 9 - Industry Trends
Neil Canavan
Medical Writer
Download PDF

Pulmonary arterial hypertension (PAH) is a chronic, debilitating, and life-threatening disease of the pulmonary vasculature characterized by remodeling of the small pulmonary arteries. The estimated prevalence of PAH in the United States is 12.4 cases per 1 million people, with an annual incidence of 2.3 cases per 1 million.1 Although these figures suggest that the disease is relatively rare, the societal impact is significant; morbidity and mortality rates for patients with PAH are high, and high-cost hospital stays are common.

Michael Lacey, MSc, of OptumInsight, Eden Prairie, MN, and colleagues set out to investigate the rates and costs of rehospitalization of patients with PAH within 1 year of their initial hospitalization, based on the knowledge that patients with PAH are frequently rehospitalized, leading to a high burden to the US healthcare system, as well as to patients and payers. They presented their findings at the 2013 Academy of Managed Care Pharmacy (AMCP) Nexus meeting.2

According to this analysis by Lacey and colleagues, more than 75% of patients with PAH are indeed readmitted to the hospital within 1 year of an initial PAH- related hospitalization, and of those who are readmitted, more than 20% are back in the hospital within 30 days of their initial discharge, which translates to a significant clinical and economic burden.

Study Scope
The effort by Lacey and colleagues to establish the scope of the financial burden of PAH was in part motivated by recent efforts by Medicare to reduce rehospitalization rates through reimbursement adjustments.

To explore this issue, the investigators used the Optum Research Database (which is affiliated with OptumInsight), using a managed care database that included approximately 30 million members during the study period, from January 2007 through December 2011. The investigators generated the study cohort of patients with PAH who have had medical and pharmacy claims using a commercial plan and a Medicare Advantage health insurance plan. Initial hospitalization was defined as the admission that followed the first PAH-related claim (including medications, diagnostics, and other types of claims). Of the 4009 patients who were identified with PAH, 2275 (56.7%) experienced at least 1 PAH-related hospitalization during the study period. Of these patients, 1203 (52.9%) were rehospitalized at least once during the study period.

Of this latter group, approximately 255 (21.2%) patients were readmitted for the second time within the first 30 days of the initial hospitalization, and 954 (79.1%) were readmitted at least once within the first year after initial hospital discharge.

Overall, of all the patients with PAH who were hospitalized during the study period from January 2007 through December 2011, 39.2% were rehospitalized more than once.

Hospitalization Costs, Length of Stay The results showed that the cost of the initial hospitalization for a patient with PAH was $30,286, and the average length of stay (LOS) was 11 days. The average cumulative cost per a rehospitalized patient with PAH was $71,622, with an average LOS of 24.5 days.

As shown in the Table, the cumulative cost of rehospitalization in the first year after discharge, excluding the initial discharge, was $95,254 per hospitalization for a patient a with commercial insurance plan compared with $36,543 for a member with Medicare Advantage coverage.

When including the initial hospitalization, the total average cost of both types of insurance coverage was $101,908; the total hospitalization, including the initial hospitalization, was $134,830 for commercially insured patients and $53,039 for patients with Medicare Advantage (Table).


Table

The average LOS also differed by insurance type, with a higher LOS—28.5 days—seen in patients with Medicare Advantage coverage compared with 21.7 days in patients with commercial insurance coverage.

Based on these results, Lacey and colleagues concluded that, “PAH is characterized by frequent re-hospitalizations with subsequent substantial costs and LOS. This highlights the high morbidity of PAH and the need for more effective therapies [for] reducing the morbidity burden and associated hospitalizations.”

New Medications Approved for PAH
As luck would have it, in October 2013, the US Food and Drug Administration (FDA) approved 2 new therapies for the treatment of patients with PAH.

Riociguat (Adempas; Bayer Healthcare Pharmaceuticals) was approved by the FDA on October 8, 2013, for the treatment of patients with pulmonary hypertension, as well as those with PAH. Riociguat is a first-in-class drug of the soluble guanylate cyclase stimulators and has a boxed warning about the potential harm this medication has on a fetus.

A few days later, on October 18, 2013, on the heels of the AMCP meeting, the second agent, macitentan (Opsumit; Actelion Pharmaceuticals), was approved by the FDA for the treatment of patients with PAH. Macitentan is an oral dual endothelin receptor antagonist, and it, too, carries a boxed warning about the potential harm to a fetus.

These 2 new drugs are the first medications in 5 years to be approved by the FDA for the treatment of PAH.

Commenting on the FDA approval of these 2 newest medications for patients with PAH, Rino Aldreghetti, President of the Pulmonary Hypertension Association, a patient advocacy group, said, “Of the 7,000 rare diseases, only three have as many or more treatments available.” He added, “We are fortunate to have a strong and growing research community with great communication and cooperation. That has helped foster industry interest in exploring new options for our patients.”3

New treatment options, yes. But will they bring down costs? Potentially, if they can reduce the clinical burden of PAH and prevent rehospitalization in this patient population. Time will tell.

References
  1. Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011;139:128-137.
  2. Lacey M, Buzinec P, Hunsche E, et al. Pulmonary hypertension-related rehospitalization among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension in the US. Poster presented at the Academy of Managed Care Pharmacy Nexus Meeting; San Antonio, TX; October 15-18, 2013.
  3. Pulmonary Hypertension Association. Eleventh PH drug approved, the second in just ten days. PH Research news; October 18, 2013. www.phassociation.org/ResearchNews. Accessed December 8, 2013.
Related Items
Value-Based Agreements in Healthcare: Willingness versus Ability
Gary Branning, MBA, Michael Lynch, CPA, MBA, Kathryn Hayes
September 2019 Vol 12, No 5 published on September 17, 2019 in Industry Trends
US Healthcare Trends and Contradictions in 2019
F. Randy Vogenberg, PhD
February 2019 Vol 12, No 1 published on February 6, 2019 in Industry Trends
A Shift in Party Majority, a Shift in Priority? What the Pharmaceutical Industry Can Expect
Gary Branning, MBA, Randy Ross, BA, Kathryn Hayes
February 2019 Vol 12, No 1 published on February 6, 2019 in Industry Trends
FDA Commissioner Outlines New Plan to Increase Biosimilars by Balancing Innovation and Competition
Eileen Koutnik-Fotopoulos
November 2018 Vol 11, No 8 published on November 30, 2018 in Industry Trends
New Rivals: Integrating Health Benefits to Provide Comprehensive Patient Care
Gary Branning, MBA, Martha Vater
April 2018 Vol 11, No 2 published on April 13, 2018 in Industry Trends
Last modified: December 17, 2013
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME